(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 February 2002 (28.02.2002)

PCT

(10) International Publication Number
WO 02/016409 A3

(51) International Patent Classification[7]: C07K 7/08, 14/705, A61K 47/48, A61P 37/08

(21) International Application Number: PCT/EP01/09576

(22) International Filing Date: 17 August 2001 (17.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0020717.5 22 August 2000 (22.08.2000) GB

(71) Applicants *(for all designated States except US)*: **SMITHKLINE BEECHAM BIOLOGICALS S.A.** [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE). **ACAMBIS RESEARCH LIMITED** [GB/GB]; Peterhouse Technology Park, 100 Fulbourn Road, Cambridge CB1 9PT (GB).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **FRIEDE, Martin** [GB/BE]; c/o GlaxoSmithKline Biologicals, Rue de l'Institut, 89, B-1330 Rixensart (BE). **MASON, Sean** [GB/GB]; c/o Peptide Therapeutics Limited, Peterhouse Technology Park, 100 Fulbourn Road, Cambridge CB1 9PT (GB). **TURNELL, William, Gordon** [GB/GB]; c/o Peptide Therapeutics Limited, Peterhouse Technology Park, 100 Fulbourn Road, Cambridge CB1 9PT (GB). **VINALS Y BASSOLS, Carlota** [BE/BE]; GlaxoSmithKline Biologicals, Rue de l'Institut 89, B-1330 Rixensart (BE).

(74) Agent: **EASEMAN, Richard, Lewis**; GlaxoSmithKline, Corporate Intellectual Property (CN9.25.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,

*[Continued on next page]*

(54) Title: VACCINE IMMUNOGENS COMPRISING DISULPHIDE BRIDGED CYCLISED PEPTIDE AND USE THEREOF IN THE TREATMENT OF ALLERGIES




(57) Abstract: The present invention relates to a novel chemical process for the covalent conjugation of disulphide bridge cyclised peptides to immunogenic carrier molecules by thio-ether linkages to form vaccine immunogens. In particular, the novel chemistry involves reacting a thiolated carrier with a cyclic peptide containing a disulphide bridge, which cyclic peptide (herein a disulphide bridge cyclised peptide) has attached to it, usually *via* a linker, a reactive group capable of forming thio-ether bonds with the carrier. The invention further relates to activated peptide intermediates of the process, medicaments produced by the process, pharmaceutical compositions containing the medicaments, and the use of the pharmaceutical compositions in medicine. The process of the present invention is particularly useful for the preparation of highly pure immunogens for vaccines, comprising disulphide bridge cyclised peptides. Also novel immunogens are provided, based on peptides derived from the sequence of human IgE, which are useful in the immunotherpay of allergy. Accordingly, the invention relates also to a process for conjugation of IgE disulphide bridge cyclised peptides to carries, immunogens produced by the process and vaccines and pharmaceutical compositions comprising them and their use in the treatment of allergy.

WO 02/016409 A3

LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

**(84) Designated States** *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report*

**(88) Date of publication of the international search report:**
29 August 2002

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*